No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects

• Main Authors: Lin Zhao (Author), Yi Sun (Author), Xiaoran Yang (Author), Ling Tian (Author), Lize Li (Author), Fangfang Wang (Author), Xiaoye Niu (Author), Lei Diao (Author), Haiyan Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cardiotoxicity and QT interval prolongation have been a common cause of withdrawal of drugs from the market. FCN-437c is an oral, second-generation, potent, and selective CDK4/6 inhibitor for the treatment of patients with HR+/HER2- metastatic breast cancer. A single-center, double-blind, randomized...